The US has banned India’s largest drugmaker Ranbaxy from producing and distributing drugs for the US market from its Toansa facility in Punjab.
The US drug regulator said there had been “significant” manufacturing violations at the facility.
It alleged that staff had retested materials after those items had failed initial tests “in order to produce acceptable findings”.
Other Ranbaxy units have also come under scrutiny by the US in the past.
The US Food and Drug Administration (FDA) has previously banned products from the company’s facilities in Paonta Sahib, Dewas and Mohali.
“We are taking swift action to prevent substandard-quality products from reaching US consumers,” Carol Bennett, acting director of the FDA’s Office of Compliance, said in a statement.
Ranbaxy said in a statement that it had “voluntarily and proactively suspended shipments” from the facility to the US after it received the inspection findings earlier this month.
“This development is clearly unacceptable and an appropriate management action will be taken upon completion of the internal investigation,” said Arun Sawhney, chief executive of Ranbaxy.
The firm’s shares fell as much as 20% on the FDA ruling.
Daily Business Feature: Growth in the 21st century will be made through technology and innovation. Payment processors are using new service solutions to solve old problems.
